Updates from The Motley Fool

Latest updates on Juno Therapeutics from Fool.com.  The Fool has written over 100 articles on Juno Therapeutics.
2016's Worst Clinical Failures

It's been a rough year for drugmakers, but late clinical-stage failures made it especially tough ...

The Unsung Heroes of CAR-T

Investors are well aware of the big names in CAR-T therapies, but these companies are working beh...

Stock Performance

View Interactive JUNO Charts
Sponsored by

Key Data Points

Primary metrics and data points about Juno Therapeutics.
Current Price: $23.30
Prev Close: $25.52
Open: $25.43
Bid: $23.32
Ask: $23.40
Day's Range: $23.18 - $25.45
52wk Range: $17.52 - $49.72
Volume: 2,608,959
Avg Vol 1,324,547
Market Cap: $2B
P/E (ttm): -10.25
EPS (ttm): ($2.49)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Juno Therapeutics.
CAPS Rating 5 out of 5
151 Outperform
3 Underperform
CAPS All Stars
37 Outperform
1 Underperform

How do you think Juno Therapeutics will perform against the market?

You pick for Juno Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS

CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Hans Bishop, CEO

85% Approve

Based on 7 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Juno Therapeutics.


  • Exchange: NASDAQ